Jonathan Slonin compensation by year
Pacira BioSciences Summary Compensation Table · all 4 fiscal years held| Component | FY2021 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $426,193 | $490,225 | $535,000 | $555,989 |
| Bonus | $212,900 | $220,300 | $247,438 | $257,335 |
| Stock awards | $667,624 | $424,203 | $1,717,324 | $2,464,488 |
| Option awards | $639,479 | $438,138 | $131,038 | $0 |
| Non-equity incentive | $145,602 | $0 | $227,295 | $258,342 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $30,557 | $20,347 | $20,833 | $39,768 |
| Total | $2,122,355 | $1,593,213 | $2,878,928 | $3,575,922 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Pacira BioSciences, Inc. DEF 14A filed April 28, 2026, accession 0001104659-26-050353, and prior-year filings.
How this page was built: the Pacira BioSciences, Inc. filed document, accession 0001104659-26-050353. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 93,600 | $2,422,368 | — |
| RSU | 40,725 | $1,053,963 | — |
| RSU | 5,474 | $141,667 | — |
| RSU | 3,750 | $97,050 | — |
| RSU | 2,475 | $64,053 | — |
| Option | 10,310 | — | $38.74 |
| Option | 5,625 | — | $32.07 |
| Option | 3,100 | — | $59.39 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Pacira BioSciences, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2025 proxy (filed April 28, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-17 | Sale | 10b5-1 | 3,040 | $23.23 | 216,383.65 |
| 2026-06-03 | Tax withholding | — | 4,728 | $22.32 | 218,912.18 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Pacira BioSciences’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Frank Lee | Chief Executive Officer and Director | $11,636,917 |
| Brendan Teehan | Chief Commercial Officer | $4,007,677 |
| Jonathan Slonin · this page | Chief Medical Officer | $3,575,922 |
| Kristen Williams | Chief Administrative Officer and Secretary | $3,180,476 |
| Shawn Cross | Chief Financial Officer | $1,029,076 |
The full Pacira BioSciences compensation record
free company briefThis page is one person within Pacira BioSciences's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Pacira BioSciences proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Pacira BioSciences's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Pacira BioSciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.